duocarmycin a

Duocarmycin A, an antitumor antibiotic, is a DNA alkylator and efficiently alkylates adenine N3 at the 3′ end of AT-rich sequences in the DNA. Duocarmycin A, as a chemotherapeutic agent, results in HLC-2 cells typically apoptotic changes.

Duocarmycin A (GMP) refers to the GMP grade reagents of Duocarmycin A. Duocarmycin A is an anti-tumor antibiotic that belongs to the class of DNA methylating agents. It can effectively methylate the N3 of adenine at the 3' end of sequences rich in adenine in DNA. As a chemotherapy drug, Duocarmycin A causes typical apoptotic changes in HLC-2 cells.

Duocarmycin analog-2, a potent DNA alkylating agent, exhibits antitumor effects and can be utilized in the synthesis of immunocouplers.

Duocarmycin Analog is used as an DNA alkylator and ADC cytotoxin. Duocarmycin Analog is an analog of Duocarmycin.

Duocarmycin GA, an antibody drug conjugate (ADC) toxin and a DNA alkylating agent, effectively targets and binds in the minor groove of DNA. It is particularly potent against multi-drug resistant cell lines, offering a strategic approach in combating resistance.

Duocarmycin MA, an antibody drug conjugates (ADCs) toxin, is a DNA alkylating agent that binds in the minor groove and can be used against multi-drug resistant cell lines.

Duocarmycin MB, an antibody-drug conjugate (ADCs) toxin, is a DNA alkylating agent that binds in the minor groove and can be used against multi-drug resistant cell lines.

Duocarmycin is a DNA minor groove binding alkylating agent and explored as drug–antibody conjugates (ADCs) . Duocarmycin is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity.

Duocarmycin TM is a DNA alkylator. Duocarmycin TM is an exceptionally potent antitumor antibiotic.

(S)-Seco-Duocarmycin SA is a DNA alkylating agent and antibiotic with potent antitumor activity that can be used to synthesize ADC compounds.

Seco-Duocarmycin SA is a highly potent DNA alkylator used as an ADC cytotoxin.

Fmoc-Val-Cit-PAB-Duocarmycin TM is a drug-linker conjugate intended for antibody-drug conjugation (ADC), employing the antitumor antibiotic Duocarmycin TM and connected via the linker Fmoc-Val-Cit-PAB.

MC-Val-Cit-PAB-duocarmycin is an antibody-drug conjugate (ADC) linker that combines duocarmycin, a potent DNA minor groove-binding alkylating agent, with an antitumor drug through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

Mal-PEG4-VC-PAB-DMEA-duocarmycin SA is a thiol-reactive Drug-linker. Duocarmycin SA is a highly effective and orally active cytotoxic agent that can be used in the synthesis of antibody-drug conjugates (ADCs).

MA-PEG4-VC-PAB-DMEA-duocarmycin TM is a thiol-reactive Drug-linker. Duocarmycin TM is an effective antibiotic with anti-tumor activity, and is commonly used in the synthesis of antibody-drug conjugates (ADC).

Mal-PEG4-VC-PAB-DMEA-duocarmycin-DM is a thiol-reactive Drug-linker. Duocarmycin DM is a DNA alkylating agent that can be used as a toxin for ADC conjugates and is employed in the synthesis of antibody-drug conjugates (ADCs).

DBCO-PEG4-VC-PAB-DMEA-Duocarmycin SA is a click-reactive Drug-linker that contains a DBCO group and can undergo strain-promoted acylnitridation addition reaction (SPAAC) with molecules containing azide groups. Duocarmycin SA is a highly effective and orally active cytotoxic agent. DBCO-PEG4-VC-PAB-DMEA-Duocarmycin SA can be used in the synthesis of antibody-drug conjugates (ADC).

Seco-DUBA is an anticancer DNA alkylating agent and prodrug of DUBA, which can be used as a cytotoxic antibody-drug conjugate (ADC). It has an IC50 of 18 nM against KB and 430 pM against SK-OV-3, and can be converted into DUBA with higher stability and activity in vivo.

Pibrozelesin is a water-soluble derivative of duocarmycin B2 that alkylates DNA by binding to adenine-thymine (A-T)-rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and inducing apoptosis.

Duocarmycin DM, a toxin for antibody-drug conjugates (ADCs), functions as a DNA minor-groove alkylator. It exerts its anticancer activity through a distinct curved indole structure combined with a spirocyclopropylcyclohexadienone electrophile [1] [2].

Vobramitamab (AEX-4089) is a humanized monoclonal antibody (mAb) targeting the B7-H3 antigen (CD276) which is conjugated to the prodrug seco-duocarmycin hydroxybenzamide azaindole (seco-DUBA) through a enzymatically cleavable peptide-based linker, thereby creating the investigational antibody-drug conjugate (ADC) known as MGC018.

NMS-P528, a Duocarmycin derivative, serves as an ADC payload and is utilized in the synthesis of NMS-P945 [1].

MA-PEG4-VC-PAB-DMEA-Duocarmycin DM is a drug-linker conjugate for ADC, utilizing the anticancer antibiotic Duocarmycin DM, linked via MA-PEG4-VC-PAB-DMEA [1] [2].

Compound LD-1 (G3-VC-PAB-DMEA-Duocarmycin DM) is a linker molecule based on duocarmycin that is utilized in the preparation of ADCs [1].